206 related articles for article (PubMed ID: 34978889)
21. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
22. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
[TBL] [Abstract][Full Text] [Related]
23. Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Agniswamy J; Shen CH; Wang YF; Ghosh AK; Rao KV; Xu CX; Sayer JM; Louis JM; Weber IT
J Med Chem; 2013 May; 56(10):4017-27. PubMed ID: 23590295
[TBL] [Abstract][Full Text] [Related]
24. Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR
Agniswamy J; Kneller DW; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2021 Aug; 566():30-35. PubMed ID: 34111669
[TBL] [Abstract][Full Text] [Related]
25. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
[TBL] [Abstract][Full Text] [Related]
26. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
[TBL] [Abstract][Full Text] [Related]
27. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
28. Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity.
Bulut H; Hattori SI; Aoki-Ogata H; Hayashi H; Das D; Aoki M; Davis DA; Rao KV; Nyalapatla PR; Ghosh AK; Mitsuya H
Sci Rep; 2020 Jun; 10(1):10664. PubMed ID: 32606378
[TBL] [Abstract][Full Text] [Related]
29. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
30. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
31. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
32. Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Kovela S; Brindisi M; Osswald HL; Sekhara Reddy B; Agniswamy J; Wang YF; Aoki M; Hattori SI; Weber IT; Mitsuya H
ChemMedChem; 2018 Apr; 13(8):803-815. PubMed ID: 29437300
[TBL] [Abstract][Full Text] [Related]
33. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
[TBL] [Abstract][Full Text] [Related]
34. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
[TBL] [Abstract][Full Text] [Related]
35. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
36. Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism.
Wang R; Zheng Q
Langmuir; 2020 Nov; 36(46):13817-13832. PubMed ID: 33175558
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.
Wong-Sam A; Wang YF; Kneller DW; Kovalevsky AY; Ghosh AK; Harrison RW; Weber IT
J Mol Graph Model; 2022 Dec; 117():108315. PubMed ID: 36108568
[TBL] [Abstract][Full Text] [Related]
38. HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.
Ghosh AK; Sarkar A; Mitsuya H
Med Res Arch; 2017 Apr; 5(4):. PubMed ID: 29984302
[TBL] [Abstract][Full Text] [Related]
39. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
Hidaka K; Kimura T; Sankaranarayanan R; Wang J; McDaniel KF; Kempf DJ; Kameoka M; Adachi M; Kuroki R; Nguyen JT; Hayashi Y; Kiso Y
J Med Chem; 2018 Jun; 61(12):5138-5153. PubMed ID: 29852069
[TBL] [Abstract][Full Text] [Related]
40. Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.
Chang YC; Yu X; Zhang Y; Tie Y; Wang YF; Yashchuk S; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2012 Apr; 55(7):3387-97. PubMed ID: 22401672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
